Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation

Rhea-AI Summary

Therapeutic Solutions International, Inc. (TSOI) reveals groundbreaking data showing enhanced gene therapy effects with JadiCell administration. The company demonstrated a significant increase in therapeutic cell production by combining gene therapy with JadiCell, particularly effective in treating hormone-producing cell deficiencies. Dr. Thomas Ichim and Timothy Dixon express optimism about the potential impact on clinical translation and seek collaborators for further development.

Positive

• JadiCell administration boosts gene therapy-mediated production of therapeutic cells in vivo.
• Effective treatment demonstrated in models of gene therapy-induced cellular differentiation/transdifferentiation.
• Potential to accelerate clinical implementation of gene therapy for therapeutic cell creation.
• Therapeutic Solutions International focuses on regenerative medicine and immunology to drive new therapeutic approaches.
• Seeking collaborators/licensees to advance regenerative gene therapy technology.

Negative

• None.

Clinical Stage Company Discloses Unanticipated Synergy Between Mesenchymal Stem Cell Therapy and Genes

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.

In a series of experiments the Company showed that animals made deficient in a hormone producing cells can be treated with great efficacy by combining differentiation promoting gene therapy with JadiCell administration. The observation was made in several models of gene therapy induced cellular differentiation/transdifferentiation and was reproducible with other cells of the mesenchymal stem cell family, although the JadiCell proved the most efficacious.

“We are living in a historic time in which gene therapy has been successfully used to change cells within the body of a patient. For example, insertion of one type of gene can generate blood vessel cells¹, another gene can generate cardiac cells², yet others can generate muscle cells³,” said Dr. Thomas Ichim, Board Member, and co-inventor of the technology. “Unfortunately, the biggest hurdle to clinical translation of such approaches is low efficacy. We are confident that the finds disclosed today will help accelerate the widespread clinical implementation of gene therapy mediated creation of therapeutic cells in the body.”

“Therapeutic Solutions International is an ‘Innovation Factory’ that leverages its core expertise in regenerative medicine and immunology to hyper accelerate advancement of new therapeutic approaches from the lab to the patient,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “We are currently seeking collaborators/licensees to implement this new technology of regenerative gene therapy.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 McCoy et al. A miRNA cassette reprograms smooth muscle cells into endothelial cells. FASEB J. 2022 Apr;36(4):e22239.
2 Bektik et al. Production of Cardiomyocyte-Like Cells by Fibroblast Reprogramming with Defined Factors. Methods Mol Biol . 2021:2239:33-46.
3 Almeida et al. Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders. J Vis Exp. 2021 Apr 3:(170).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226116362/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

How does JadiCell administration enhance gene therapy effects for Therapeutic Solutions International, Inc. (TSOI)?

JadiCell administration increases gene therapy-mediated production of therapeutic cells, particularly effective in treating hormone-producing cell deficiencies.

What did the experiments show regarding the combination of gene therapy and JadiCell administration for Therapeutic Solutions International, Inc. (TSOI)?

Experiments demonstrated a significant increase in therapeutic cell production by combining gene therapy with JadiCell, showing efficacy in treating hormone-producing cell deficiencies.

What is the focus of Therapeutic Solutions International, Inc. (TSOI) in terms of therapeutic approaches?

Therapeutic Solutions International focuses on regenerative medicine and immunology to drive new therapeutic approaches.

Who expressed optimism about the potential impact of the disclosed findings from Therapeutic Solutions International, Inc. (TSOI)?

Dr. Thomas Ichim and Timothy Dixon expressed optimism about the potential impact on clinical translation of gene therapy for therapeutic cell creation.

What is Therapeutic Solutions International, Inc. (TSOI) currently seeking in relation to their new technology?

Therapeutic Solutions International is seeking collaborators/licensees to implement their new technology of regenerative gene therapy.